CASI Pharmaceuticals Announces Safety Monitoring Committee Recommendation to Escalate CID-103 Dose to Next Cohort in Phase 1 Immune Thrombocytopenia (ITP) Study
互联网科技包装(US:ITP) Accessnewswire·2025-09-08 21:00- CID-103 is a potential best-in-class, clinical stage anti-CD38 monoclonal antibody - Safety profile observed in first four dose cohorts supports continued development - No serious adverse events or dose-limiting toxicities have been reported SOUTH SAN FRANCISCO, CALIFORNIA / ACCESS Newswire / September 8, 2025 / CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing innovative therapies for patients with organ transplant rejection and autoimmune diseases ...